<DOC>
	<DOCNO>NCT01977209</DOCNO>
	<brief_summary>The investigator ' experimental study find gossypol natural inhibitor apyrimidinic endonuclease 1 ( APE1 ) clinical study observe high expression APE1 relative platinum-resistance non-small cell lung cancer . Thus purpose study find whether gossypol improve sensitivity cisplatin-based chemotherapy non-small cell lung cancer apurinic apyrimidinic endonuclease 1 ( APE1 ) high expression</brief_summary>
	<brief_title>Gossypol Combined With Docetaxel Cisplatin Scheme Advanced Non Small-cell Lung Cancers With APE1 High Expression</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>Histologic cytologic diagnosis NSCLC , Stage IIIB/IV . Males females 18 Years 75 Years . No prior cisplatinbased chemotherapy , surgery radiotherapy administer , interval least four week . The interval target therapy EGFR TKI 2 week . Performance status 0 , 1 ECOG criterion . Expected survival three month . At least one unidimensional measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST . 2000 ) . Patients brain / meningeal metastasis history , metastasis must treat operation radiotherapy ) , clinically stable least 2 month . Adequate hematologic ( neutrophil count &gt; = 1,500/uL , platelet &gt; = 100,000/uL ) , hepatic ( transaminase = &lt; upper normal limit ( UNL ) x2.5 , bilirubin level = &lt; UNLx1.5 ) , renal ( creatinine = &lt; UNL ) function . Patient compliance allow adequate followup . Informed consent patient patient 's relative . APE1 IHC ( ++ +++ ) . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 2 month trial . If male , use approve contraceptive method study 2 month afterwards . Females childbearing potential must urine negative HCG test within 7 day prior study enrollment . No concomitant prescription include cyclosporin A , valproic acid , phenobarbital , phenytoin , ketoconazole . Inability comply protocol study procedure . Medically uncontrolled serious heart , lung , neurological , psychological , metabolic disease . Second primary malignancy clinically detectable time consideration study enrollment . Pregnant breastfeeding . Enrollment study within 30 day . Brain metastasis symptom . Hypokalemic periodic paralysis history .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>NSCLC ; Gossypol ; APE1 ; Chemotherapy</keyword>
</DOC>